
LGM Pharma Boosts US Manufacturing with Additional $9 Million Investment
LGM Pharma invests an additional $9 million to expand US manufacturing, bringing total investment to $15 million across its Texas and Colorado facilities.

LGM Pharma invests an additional $9 million to expand US manufacturing, bringing total investment to $15 million across its Texas and Colorado facilities.

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

US API specialist LGM Pharma has acquired the formulation development and drug product contract manufacturing business of specialty pharma company Nexgen Pharma for an undisclosed sum.
